Flavoxate
As of the edition of 20 October 2026, Flavoxate is a small molecule: marketed, first approved in 1975 (ES); acts on PDE4A, PDE4B and PDE4C and 5 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Urispas
- First approved
- 1 May 1975 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Johnson & Johnson; 3 holders in all
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Flavoxate.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PDE8A | High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | O60658 |
| PDE8B | High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B | O95263 |
| PDE4A | 3',5'-cyclic-AMP phosphodiesterase 4A | P27815 |
| PDE4B | 3',5'-cyclic-AMP phosphodiesterase 4B | Q07343 |
| PDE4C | 3',5'-cyclic-AMP phosphodiesterase 4C | Q08493 |
| PDE4D | 3',5'-cyclic-AMP phosphodiesterase 4D | Q08499 |
| PDE7A | High affinity 3',5'-cyclic-AMP phosphodiesterase 7A | Q13946 |
| PDE7B | 3',5'-cyclic-AMP phosphodiesterase 7B | Q9NP56 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Acquired holder | 2008 to now |
| GSK | Earlier holder |